- Our Technology
Engineered for fragile regenerative payloads. Built for controlled upper-skin delivery.
ExoGenis is a controlled microtip delivery platform designed to support local placement of active formulations beyond passive topical absorption
First MVP: exosome-associated formulation for aesthetic and dermatological recovery
Controlled
upper-skin access
ExoGenis uses short dissolvable microtips designed to create temporary microchannels in the upper skin layers. The system is being developed to support controlled local placement of fragile active formulations without an injection step.
- No retained solid needles
- Controlled microchannel-based access
- Designed for upper-skin interaction
- Compatible with professional clinic workflows
- MVP uses an exosome-associated formulation first
How it works
Apply. Create microchannels. Release. Remove.
APPLY
PATCH
Applied to clean, dry skin as part of a professional or clinic-guided protocol.
.svg)
FORM
MICROCHANNELS
Designed for minimally invasive superficial skin interaction to establish safe delivery paths.
Release
Bioactive Tips
Microtips dissolve during application and release the active formulation locally.
Remove
Backing
The removable backing is taken off after application, with no retained solid needles
Designed for professional skin workflows
ExoGenis is designed as a clinic-friendly delivery step that can be added after selected aesthetic procedures or used between visits as part of a clinic-guided maintenance protocol.
The pilot kit format is designed to support professional handling, protocol consistency, follow-up, and repeat-use evaluation.
One delivery architecture. First MVP payload. Future dermatology paths.
ExoGenis is built around a biologic-compatible microtip architecture. The first MVP uses an exosome-associated formulation, while future payloads and dermatology use cases will be selected only after technical, safety, and clinical validation.
ExoGenis starts with an exosome-associated formulation for aesthetic recovery and between-treatment maintenance. Future payloads and dermatology use cases will be selected only after delivery, safety, endpoint, and regulatory validation.
CURRENT MVP
Exosome-associated formulation
First payload for aesthetic recovery and between-treatment maintenance.
FUTURE PAYLOAD PATH
Growth factors / biologic signals
Potential future payload category after stability, release, and safety validation.
FUTURE PAYLOAD PATH
Peptides / fragile actives
Explored only where controlled local delivery creates a clear advantage over topical use.
DERMATOLOGY DISCOVERY
Clinician-defined payloads
Future dermatology paths will be selected with advisors based on clinical need, endpoint feasibility, and safety.
RESEARCH PATH
Larger biologics
Exploratory only. Requires proof of payload stability, release, localization, and safety.
FUTURE OPTIONALITY
Combination protocols
Potential long-term path after the first MVP and delivery evidence are established.
Not just
microneedle hardware.
A biologic delivery system
built for clinic use.
built for clinic use.
MVP first: exosome-associated formulation for aesthetic recovery and maintenance.
Platform later: additional payloads only after delivery, release, safety, and endpoint evidence.
Dermatology path: advisor-led selection of payload, indication, comparator, and case-study design.
From prototype → clinical adoption
Built on validated technology, now moving into clinical deployment with partner clinics
MVP & prototyping
planned
Core delivery system built and functionally validated.
Technical validation
next
Reproducibility, stability, and performance testing ongoing.
Pilot manufacturing
ongoing
Scale-up and manufacturing readiness in progress.
Clinical pilots
Completed
Clinical deployment with partner clinics (2026).
Interested in partnering with us?
We collaborate with aesthetic manufacturers and pharmaceutical labs to integrate our delivery system with your active ingredients.